A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis
- Substances:–
France- Participants:18–64 years
- Sponsor:Zenas Biopharma (USA) LLC
Rare diseases
Investigational molecules
Locations
Back to France40 clinical trials in Poissy, France. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in FranceEssaisCliniques.fr(opens in a new tab)
France
France
France
France
France
France
France
France
France
France
France
FranceThe busiest research cities in the country
What the registry says about research in the country
Extensive research focusing on Multiple Sclerosis treatments, including innovative therapies and comparative studies of various medications. Studies evaluate new treatment approaches like anti-CD20 maintenance and de-escalation strategies.
Multiple clinical trials are testing novel therapeutic agents to reduce disease activity and improve patient outcomes.
Critical research in neonatal medicine addressing various conditions affecting premature infants and newborns, including respiratory distress syndrome and hyperglycemia management.
Studies focus on improving survival rates and developing better treatment protocols for vulnerable newborns.
Innovative research examining cardiovascular health in high-risk populations, particularly focusing on prevention strategies in diabetic patients without prior cardiovascular events.
Clinical trials evaluating new treatment combinations to reduce cardiovascular events in at-risk populations.
Tell us about your condition – we search every trial in Europe and connect you with the right site.